A recent study has shed light on the mechanism by which ketamine, a fast-acting antidepressant, exerts its therapeutic effects on depression. Even for patients who have not responded to other medications, ketamine has shown to be highly effective. However, the precise brain mechanisms behind its rapid treatment effects have long remained elusive.
Researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, who have been delving into the reasons why ketamine is a good treatment option for some individuals with depression, have made a significant discovery. Their findings suggest that the antidepressant effects of ketamine are intricately linked to the brain’s opioid system.
The study, led by King’s College London and published in the prestigious journal Nature Medicine, involved 26 individuals with clinically diagnosed depression. These participants were administered a low dose of ketamine infusion during two separate sessions, while undergoing neuroimaging.
Prior to receiving the ketamine infusion, in one session, the participants were given naltrexone, a drug that blocks the opioid receptors in the brain. In the other session, they were given a placebo.
During the infusion, the participants were closely monitored using a brain scanner with a technique called magnetic resonance spectroscopy (MRS). MRS was used to measure dynamic changes in a brain chemical known as glutamate. Twenty-four hours after the infusion, when the antidepressant effects of ketamine typically peak, depressive symptoms were evaluated using the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS).
The researchers found that blocking the opioid system not only reduced the brain’s glutamatergic response but also diminished the antidepressant effects observed the following day. This strongly indicates that the opioid system plays a crucial role in mediating the antidepressant response to ketamine.
The study also unearthed a sex-related effect. The impact of naltrexone on glutamatergic activity was more pronounced in males with depression compared to females with depression.
These new insights into how ketamine works differently in different individuals are essential for the development of personalized treatments.
The research was funded by the Medical Research Council, the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre, and the NIHR King’s Clinical Research Facility.
Ketamine has often made headlines for negative reasons. However, at low doses, it shows great potential in providing relief from the symptoms of depression.
Dr Luke Jelen, the lead author of the study and a Clinical Lecturer in Psychiatry at IoPPN King’s College London, stated, “Understanding whether the opioid system is involved in ketamine’s antidepressant effects is a really important question, considering how much we still don’t know about how ketamine works. Our study shows that the opioid system is involved and offers insight into how it contributes to ketamine’s effects.”
The authors are eager to emphasize that ketamine is not classified as an opioid and does not bind to opioid receptors with high affinity like morphine or heroin. Instead, the findings point to a dynamic interaction between the glutamatergic and opioid systems, which may work in tandem to support ketamine’s rapid antidepressant effects.
Opiates can offer relief from the symptoms of depression, but they are highly addictive. Understanding whether and how the opioid system is involved in the effects of ketamine is crucial for understanding why ketamine works and for developing new, alternative treatments.
Currently, low-dose ketamine is being used to treat depression in private clinics and a small number of NHS clinics. At higher doses, it is also used in medical anaesthesia. However, it is also misused recreationally, and if misused, it can cause serious health problems, including irreversible damage to the bladder and kidneys.
Professor Mitul Mehta, a professor of neuroimaging & psychopharmacology at IoPPN King’s College London and Theme Lead for Experimental Medicine and Novel Therapeutics at the NIHR Maudsley BRC, said, “The brain’s different neurochemical systems work together to produce our experiences and behaviour, so it is no surprise that the opiate system may have a role in ketamine’s antidepressant effect.
We need these kinds of studies to understand exactly what the important brain mechanisms are for antidepressant effects. Understanding more about how ketamine works can lead to personalized treatments for different people, which is vital for creating safe and effective treatments.”
READ MORE
Researchers Extend Ketamine’s Antidepressant Effects to Two Months
